AU2019370629A1 - Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof - Google Patents

Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof Download PDF

Info

Publication number
AU2019370629A1
AU2019370629A1 AU2019370629A AU2019370629A AU2019370629A1 AU 2019370629 A1 AU2019370629 A1 AU 2019370629A1 AU 2019370629 A AU2019370629 A AU 2019370629A AU 2019370629 A AU2019370629 A AU 2019370629A AU 2019370629 A1 AU2019370629 A1 AU 2019370629A1
Authority
AU
Australia
Prior art keywords
msc
aoah
polypeptide
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019370629A
Other languages
English (en)
Inventor
Michael Callahan
Maria FLORIAN
Chyan-Jang LEE
Shirley H.J. MEI
Katelynn ROWE
Yan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ottawa Health Research Institute
Original Assignee
Ottawa Health Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Health Research Institute filed Critical Ottawa Health Research Institute
Publication of AU2019370629A1 publication Critical patent/AU2019370629A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019370629A 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof Abandoned AU2019370629A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
US62/752,000 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (1)

Publication Number Publication Date
AU2019370629A1 true AU2019370629A1 (en) 2021-05-20

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019370629A Abandoned AU2019370629A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Country Status (10)

Country Link
US (1) US20220010281A1 (enExample)
EP (1) EP3874029B1 (enExample)
JP (1) JP7372982B2 (enExample)
KR (1) KR20210086662A (enExample)
CN (1) CN113166729A (enExample)
AU (1) AU2019370629A1 (enExample)
ES (1) ES2962812T3 (enExample)
IL (1) IL282820A (enExample)
SG (1) SG11202103509RA (enExample)
WO (1) WO2020087160A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021360131A1 (en) * 2020-10-16 2023-05-25 Ottawa Hospital Research Institute Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
AU2009275135A1 (en) * 2008-07-21 2010-01-28 Compugen Ltd. Angiopoietin derived peptides
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
BRPI1015179A2 (pt) * 2009-06-19 2016-04-19 Merck Patent Gmbh biomarcadores e métodos para a determinação de eficácia de anticorpos anti-egfr em terapia de câncer
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
CA2859452C (en) * 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
AU2014342162B2 (en) * 2013-11-01 2020-01-02 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
EP3087101B1 (en) * 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
NZ727950A (en) * 2014-06-30 2022-07-01 Takeda Pharmaceuticals Co Mesenchymal stromal cells for treating sepsis
LT3242933T (lt) * 2015-01-08 2019-06-25 Apceth Gmbh & Co. Kg Genetiškai modifikuotos mezenchiminės kamieninės ląstelės, ekspresuojančios alfa-1 antitripsiną (aat)
JP7269733B2 (ja) * 2015-06-12 2023-05-09 レンティジェン・テクノロジー・インコーポレイテッド 操作されたｔ細胞を用いて癌を処置するための方法
EP3351254A4 (en) * 2015-09-15 2019-07-17 Kangstem Biotech Co., Ltd. COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES WITH SOD3 OVEREXPRIMATING STEM CELLS AS AN ACTIVE SUBSTANCE

Also Published As

Publication number Publication date
WO2020087160A1 (en) 2020-05-07
JP2022513379A (ja) 2022-02-07
EP3874029A1 (en) 2021-09-08
IL282820A (en) 2021-06-30
CN113166729A (zh) 2021-07-23
SG11202103509RA (en) 2021-05-28
US20220010281A1 (en) 2022-01-13
EP3874029A4 (en) 2022-08-03
EP3874029B1 (en) 2023-08-30
CA3116196A1 (en) 2020-05-07
KR20210086662A (ko) 2021-07-08
JP7372982B2 (ja) 2023-11-01
ES2962812T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
Bazzoni et al. Extracellular vesicle-dependent communication between mesenchymal stromal cells and immune effector cells
US11116819B2 (en) Methods and compositions for mobilizing stem cells
AU2017258866B2 (en) Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
Mei et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1
Leibacher et al. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells
Xu et al. CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure
Wu et al. Enhanced alleviation of aGVHD by TGF‐β1‐modified mesenchymal stem cells in mice through shifting MΦ into M2 phenotype and promoting the differentiation of Treg cells
Miller et al. Novel approaches for long-term lung transplant survival
KR20150036716A (ko) 프로스타시클린-처리된 내피 전구 세포를 사용한 폐동맥 고혈압의 치료
KR20190101360A (ko) 트레프로스티닐에 의한 msc 면역조절 특성의 향상
EP3874029B1 (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
US12202880B2 (en) HLA engineering methods and compositions for treatment of autoimmunity
Gong et al. Mesenchymal stem cell therapy for oral inflammatory diseases: research progress and future perspectives
Chen et al. Nestin+ Peyer's patch resident MSCs enhance healing of inflammatory bowel disease through IL‐22‐mediated intestinal epithelial repair
CA3116196C (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211B (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211A (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
Ma et al. Mesenchymal stem cell-derived type II alveolar epithelial progenitor cells attenuate LPS-induced acute lung injury and reduce P63 expression
US20230414668A1 (en) Cell-based therapy for viral diseases
JP2015521476A (ja) 細胞の免疫調節効果の改良
Fang et al. HGF Mediates Human Gingival Derived Mesenchymal Stem Cells Alleviated Airway Inflammation in Animal Models of Allergic Asthma
HK40008045A (en) Methods modulating immunoregulatory effect of stem cells